Innovating for impact: How natural history studies pave the way for rare disease therapies

Join Warren Huff, former CEO of Reata Pharmaceuticals, as he shares the inspiring journey behind the development of Skyclarys, the groundbreaking therapy for Friedrich’s ataxia.

In this webinar, discover how Warren and his team navigated complex regulatory systems, collaborated closely with patient organizations, and utilized innovative trial designs to bring hope to patients with this rare neurodegenerative disease.